LENZ Therapeutics (NASDAQ:LENZ) vs. Benitec Biopharma (NASDAQ:BNTC) Head-To-Head Review

Benitec Biopharma (NASDAQ:BNTC) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Benitec Biopharma and LENZ Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1	2	6	0	2.56
LENZ Therapeutics	2	1	5	0	2.38

Benitec Biopharma presently has a consensus price target of $27.00, indicating a potential upside of 111.27%. LENZ Therapeutics has a consensus price target of $29.80, indicating a potential upside of 475.29%. Given LENZ Therapeutics’ higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Benitec Biopharma.

Risk & Volatility

Benitec Biopharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Profitability

This table compares Benitec Biopharma and LENZ Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

Insider and Institutional Ownership

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Benitec Biopharma and LENZ Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92 million	($1.14)	-11.21
LENZ Therapeutics	$20.99 million	7.74	-$82.13 million	($3.60)	-1.44

Benitec Biopharma has higher earnings, but lower revenue than LENZ Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Benitec Biopharma beats LENZ Therapeutics on 7 of the 13 factors compared between the two stocks.

About Benitec Biopharma

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.